Vemurafenib and cobimetinib combined BRAF-MEK inhibitors

Melanoma

All type of patients:  2 trials  - GO28141 - Larkin

cobimetinib + vemurafenib vs vemurafenib alone

No demonstrated result
vemurafenib and cobimetinib vs vemurafenib

No demonstrated result

suggested progression or death (progression free survival PFS) by 49% (not demonstrated)




- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons